OBJECTIVE: To review the evidence on the effects of moist smokeless tobacco (snus) on smoking and ill health in Sweden. METHOD: Narrative review of published papers and other data sources (for example, conference abstracts and internet based information) on snus use, use of other tobacco products, and changes in health status in Sweden. RESULTS: Snus is manufactured and stored in a manner that causes it to deliver lower concentrations of some harmful chemicals than other tobacco products, although it can deliver high doses of nicotine. It is dependence forming, but does not appear to cause cancer or respiratory diseases. It may cause a slight increase in cardiovascular risks and is likely to be harmful to the unborn fetus, although these risks are lower than those caused by smoking. There has been a larger drop in male daily smoking (from 40% in 1976 to 15% in 2002) than female daily smoking (34% in 1976 to 20% in 2002) in Sweden, with a substantial proportion (around 30%) of male ex-smokers using snus when quitting smoking. Over the same time period, rates of lung cancer and myocardial infarction have dropped significantly faster among Swedish men than women and remain at low levels as compared with other developed countries with a long history of tobacco use. CONCLUSIONS: Snus availability in Sweden appears to have contributed to the unusually low rates of smoking among Swedish men by helping them transfer to a notably less harmful form of nicotine dependence.

We will foster cardiology worldwide not only by publishing original research, editorials, reviews, and cardiovascular flashlights, but also by a new feature of the European Heart Journal, i.e. ‘CardioPulse’. This novel feature will be incorporated into each issue at the front and will report on issues of general interest such as personalities, political aspects affecting our profession, historical vignettes, cardiology practice, national healthcare systems, and funding sources in different countries, as well as other subjects.

JN

In this sample of outpatients with coronary heart disease, the association between depressive symptoms and adverse cardiovascular events was largely explained by behavioral factors, particularly physical inactivity.

The dust is settling in the wake of the newest heralded study about statins, with doctors and patients alike now taking stock of what the results should mean in real life.

An interesting concept was presented at the American Heart Association in New Orleans today: a device that uses atrial and ventricular contractions to power a pacemaker.

The risk of sudden cardiac death following MI in community practice has declined significantly over the past 30 years. Sudden cardiac death is independently associated with heart failure but not with recurrent ischemia.

An increased risk of death from diseases other than AIDS has possibly been tied to a therapy designed to help HIV-positive people, a new study says. The results, stemming from an international study published inPLoS Medicine, found that patients receiving either of two methods of antiretroviral therapy (ART) for HIV had increased risk of death from conditions such as cardiovascular complications linked to three biomarkers: high-sensitivity C-reactive protein (hsCRP), interleukin 6 (IL-6), and D-dimer.

Tests of a single, cheap tablet combining a range of drugs that protect against heart disease and stroke have begun. Now a team funded by the Wellcome Trust in London, UK, and the British Heart Foundation, and led by Anthony Rodgers at the University of Auckland, New Zealand, has begun recruiting 700 volunteers in six countries for a pilot trial of a polypill manufactured by Dr Reddy's of Hyderabad, India.